LCT 0.01
Notification of cessation of securities - LCT
Living Cell Technologies provides notification of the cessation of options expiring on various dates at various prices.
Preliminary Final Report and 2022 Financial Statements
Living Cell Technologies has released its Preliminary Final Report (Appendix 4E) for the financial year ended 30 June 2022, highlighted by further advances in the Company’s third clinical trial of NTCELL in Parkinson’s disease.
Choroid plexus tissue shipped to Sydney as NTCELL research advances
Living Cell Technologies has advanced its Parkinson’s disease research, with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.
Quarterly Activity Report and Appendix 4C
LCT's Activity and Cashflow (Appendix 4C) report for the June quarter 2022, highlighted by the move to apply the benefits of artificial intelligence towards the Company’s third clinical trial of NTCELL in Parkinson’s disease.
Change of Director's Interest Notice - B Tuch and A Kelly
Change of Director's Interest Notice for LCT Directors, Professor Bernie Tuch and Dr Andrew Kelly.